From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Public company
Traded asLSEINDV
HeadquartersRichmond, Virginia
Key people
Howard Pien, Chairman
Shaun Thaxter, CEO
Revenue$1,093 million (2017)[1]
$193 million (2017)[1]
$58 million (2017)[1]
Number of employees
1,012 (2017)[1]

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]


The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[5]


  1. ^ a b c d "Annual Report 2017" (PDF). Indivior. Retrieved 26 March 2018.
  2. ^ a b "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. ^ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. ^ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
  5. ^ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.

External links[edit]